| Literature DB >> 24703772 |
Hanna Baurska1, Marek Kiełbiński2, Przemysław Biecek3, Olga Haus4, Bożena Jaźwiec2, Andrzej Kutner5, Ewa Marcinkowska6.
Abstract
The differentiation-inducing potential of side-chain modified analogs of vitamins D, compared to the reference compound, 1,25-dihydroxyvitamin D3, was studied in blast cells from patients with acute myeloid leukemia and in cell lines. Analogs PRI-1906 and PRI-1907 showed increased cell-differentiation activities, PRI-1907 even at a very low concentration. Our study revealed a high variability of individual patients' blasts in their susceptibility to vitamin D analogs. The blasts of the patients with normal karyotype and with mutated NPM1 reacted to analogs with stronger differentiation than the blasts of the remaining patients, while the blasts with mutated FLT3 receptor reacted with weaker differentiation than the remaining blasts.Entities:
Keywords: 1 ;25-dihydroxyvitamin D(3); Acute myeloid leukemia; Blasts; Differentiation; Flow cytometry; Personalized anticancer therapy; Statistical analysis; Vitamin D analogs
Mesh：
Substances：
Year: 2014 PMID： 24703772 DOI： 10.1016/j.leukres.2014.03.009
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156